Activation of human colon mast cells through proteinase activated receptor-2

Shao-Heng He, Yong-Song He, Hua Xie

Shao-Heng He, Hua Xie, Allergy and Inflammation Research Institute, Shantou University Medical College, Shantou 515031, Guangdong Province, China
Shao-Heng He, Yong-Song He, Immunopharmacology Group, University of Southampton, Southampton, UK

Supported by the National Natural Science Foundation of China, No. 30140023, and the Li Ka Shing Foundation, Hong Kong, China, No. C0200001

Correspondence to: Professor Shao-Heng He, Allergy and Inflammation Research Institute, Shantou University Medical College, 22 Xin-Ling Road, Shantou 515031, Guangdong Province, China. shoaehenghe@hotmail.com

Telephone: +86-754-8900405 Fax: +86-754-8900192

Received: 2003-10-10 Accepted: 2003-11-19

Abstract

AIM: To investigate the ability of agonists of PAR-2 to stimulate release of tryptase and histamine from human colon mast cells and the potential mechanisms.

METHODS: Enzymatically dispersed cells from human colons were challenged with tc-LIGRLO, tc-OLRGIL, SLIGKV, VKGILS, trypsin, anti-IgE or calcium ionophore A23187, and the cell supernatants after challenge were collected. Tryptase release was determined with a sandwich ELISA procedure and histamine release was measured using a glass fibre-based fluorometric assay.

RESULTS: Both PAR-2 agonists tc-LIGRLO-NH₂ and SLIGKV-NH₂ were able to induce dose dependent release of tryptase and histamine from colon mast cells. More than 2.5 fold increase in both tryptase and histamine release was provoked by 100 µmol/mL tc-LIGRLO-NH₂ in comparison with only 2.0 fold increase being stimulated by SLIGKV-NH₂. The reverse peptides tc-OLRGIL-NH₂ and VKGILS-NH₂, at the concentrations tested had no effect on the release of these two mediators. The maximum tryptase release elicited by tc-LIGRLO-NH₂ was similar to that induced by anti-IgE (10 µg/mL) or calcium ionophore (1 µg/mL), though the latter was a more potent stimulus for histamine release. Both histamine and tryptase release in response to tc-LIGRLO-NH₂ were completed within 3 min. Tryptase at concentrations from 1.0 to 100 µg/mL was capable of provoking a dose dependent release of tryptase as well as histamine with a maximum of 16 ng/mL tryptase and 14 ng/mL histamine release being achieved. An approximately 80% and 70% inhibition of trypsin induced release of tryptase and histamine were observed with SBTI, respectively. Pretreatment of cells with metabolic inhibitors or pertussis toxin abolished the actions of tc-LIGRLO-NH₂, SLIGKV-NH₂ and trypsin.

CONCLUSION: The agonists of PAR-2 and trypsin are potent secretagogues of human colon mast cells, which are likely to contribute to the development of inflammatory disorders in human gut.

He SH, He YS, Xie H. Activation of human colon mast cells through proteinase activated receptor-2. World J Gastroenterol 2004; 10(3):327-331

http://www.wjgnet.com/1007-9327/10/327.asp

INTRODUCTION

PAR-2 is a 7-transmembrane G protein-coupled receptor, which can be activated by serine proteinase trypsin and mast cell tryptase[11], and some synthetic peptides corresponding to the N-terminal tethered ligand sequences that are unmasked by proteolytic cleavage including SLIGKV in man[2] and SLIGRL in rodents[3].

In gastrointestinal tract, PAR-2 activation has been found to be actively involved in a number of inflammatory processes including induction of granulocyte infiltration, colon edema, tissue damage in mouse[6,7], induction of gastric mucus secretion and mucosal cytoprotection[8] in rat, excitation of submucosal neurons of guinea pig small intestine[9,10] and activation of ion secretion from human colon[11]. Moreover, upregulation of expression of PAR-2 in ulcerative colitis[12] suggested a strong possibility of involvement of mast cell tryptase and trypsin in inflammatory bowel disease.

Indeed, increased numbers of mast cells were observed in chronic ulcerative colitis[13] and Crohn’s disease[14], elevated histamine levels or enhanced histamine metabolism were found in collagenous colitis, food allergy[15], Crohn’s disease[16,17], ulcerative colitis[18,19] and allergic enteropathy[20] and increased levels of trypase were detected in ulcerative colitis[20], indicating that these two proinflammatory mediators are involved in the pathogenesis of certain gastrointestinal diseases.

We have reported previously that mast cell tryptase was able to activate mast cells[11,18], which presents a self-amplification mechanism of mast cell degranulation. Since the receptor of trypase, PAR-2 was localized on human mast cells[20] and PAR-2 agonists were reported to be capable of activating rat peritoneal mast cells[20], it is likely that PAR-2 agonists and trypsin may have ability to activate human mast cells. We therefore examined the effect of trypsin and PAR-2 agonists on tryptase and histamine release from human colon mast cells in the current study.

MATERIALS AND METHODS

Reagents

The following compounds were purchased from Sigma (St. Louis, USA): collagenase (type I), hyaluronidase (type I), soy bean trypsin inhibitor (SBTI), bovine serum albumin (BSA, fraction V), penicillin and streptomycin, calcium ionophore A23187, antimycin A, human trypsin, 2-deoxy-D-glucose, pertussis toxin. Goat anti-human IgE (inactivated) was from Serotec (Kidlington, Oxford, UK). FCS and minimum essential medium (MEM) containing 25 mM 2-hydroxyethylpiperazine-N’’-2-ethane sulphonlic acid (HEPES) were from Gibco (Paisley, Renfrewshire, UK). Peptides SLIGKV-NH₂, VKGILS-NH₂, trans-cinnamoyl-Leu-Ile-Gly-Arg-Leu- Orn-amide (tc-LIGRLO) and trans-cinnamoyl-Orn-Leu-Arg-Gly-Ile-Leu-amide

• MAST CELL AND INFLAMMATORY BOWEL DISEASE •

World J Gastroenterol 2004;10(3):327-331
World Journal of Gastroenterology
Copyright © 2004 by The WJG Press ISSN 1007-9327
(tc-OLRGIL) were >98% purity and from Meilian Corporation (Xian, China). A polyclonal antibody and a monoclonal antibody against tryptase were donated by Dr Andrew F. Walls (University of Southampton, UK). Histamine plate was from RefLab (Copenhagen, Denmark). HEPES and all other chemicals were of analytical grade.

**Dispersion of mast cells**

The mast cell dispersion procedure was similar to the one described previously.\(^\text{[21,22]}\) Human colon tissue was obtained from patients with carcinoma of colon at colectomy. Only macroscopically normal tissue was used for the study. After removal of fat, tissue was washed and chopped finely with scissors into fragments of 0.5-2.0 mm\(^3\), and then incubated with 1.5 mg/mL collagenase and 0.75 mg/mL hyaluronidase in MEM containing 2% fetal calf serum (1 g colon/10 mL buffer) for 70 min at 37 \(^\circ\)C. Dispersed cells were separated from undigested tissue by filtration through nylon gauze (pore size 100 \(\mu\)m diameter), washed and maintained in MEM (containing 10% FCS, 200 U/mL penicillin, 200 \(\mu\)g/mL streptomycin) on a roller overnight at room temperature. Mast cell purity, as determined by light microscopy after stained by alcine blue, ranged from 3.5% to 5.5%.

**Mast cell challenge**

Dispersed cells were resuspended in HEPES buffered salt solution (HBSS, pH 7.4) with 1.8 mM CaCl\(_2\) and 0.5 mM MgCl\(_2\) (complete HBSS), and 100 \(\mu\)L aliquots containing 4-6\(\times\)10\(^5\) mast cells were added to a 50 \(\mu\)L tc-LIGRLO, tc-OLRGIL, SLIGKV, VKGILS, trypsin, control secretagogue or buffer alone and incubated for 15 min at 37 \(^\circ\)C. The reaction was terminated by the addition of 150 \(\mu\)L ice cold incomplete HBSS and the tubes were centrifuged immediately (500 g, 10 min, 4 \(^\circ\)C). All experiments were performed in duplicate.

For the experiments with pertussis toxin, cells were incubated with 0.1 or 1.0 \(\mu\)g/mL pertussis toxin for four hours at 37 \(^\circ\)C, then incubated with 2-deoxy-D-glucose (10 mmol/L) and antimycin A (1 \(\mu\)mol/L) for 40 min at 37 \(^\circ\)C before challenged with stimulus. For the measurement of total histamine concentration in certain tubes, the suspension was boiled for 6 min. Supernatants were stored at -20 \(^\circ\)C until use.

**Tryptase and histamine measurement**

Tryptase concentrations were measured with a sandwich ELISA procedure with a specific polyclonal antibody against human tryptase as the capture antibody and AA5 a monoclonal antibody specific for human tryptase as the detecting antibody.\(^\text{[23]}\) Histamine concentrations were determined using a glass fibre-based fluorometric assay.\(^\text{[17]}\)

**Statistical analysis**

Data are shown as mean±SEM for the number of experiments (\(n\)) indicated, and the paired Student’s \(t\) test was applied to evaluate two independent samples. In all analyses \(P<0.05\) was taken as statistically significant.

**RESULTS**

**Induction of tryptase release by agonists of PAR-2**

Both PAR-2 agonists tc-LIGRLO-NH\(_2\) and SLIGKV-NH\(_2\) were able to induce dose dependent release of tryptase from colon mast cells (Figure 1). More than 2.5 fold increase in tryptase release was provoked by 100 \(\mu\)mol/mL tc-LIGRLO-NH\(_2\), even at a concentration as low as 1.0 \(\mu\)mol/mL tc-LIGRLO-NH\(_2\) was able to elicit a 2.2 fold increase in the release of tryptase. Although the potency of SLIGKV-NH\(_2\) appeared slightly weaker than that of tc-LIGRLO-NH\(_2\), it could still stimulate as much as two fold increase in the release of tryptase from colon mast cells. The reverse peptides tc-OLRGIL-NH\(_2\) and VKGILS-NH\(_2\) had no effect on the release of tryptase when being added at the concentrations from 0.1 to 300 \(\mu\)mol/mL (Figure 1). The quantity of tryptase released elicited by tc-LIGRLO-NH\(_2\) (100 \(\mu\)mol/mL) was similar to that induced by 10 \(\mu\)g/mL anti-IgE or 1 \(\mu\)g/mL calcium ionophore. Tryptase at the concentrations of 1.0-100 \(\mu\)g/mL was capable of provoking a dose dependent release of tryptase with a maximum of 16 ng/mL tryptase being released by 100 \(\mu\)g/mL trypsin (Figure 1). Approximately 80% trypsin induced release of tryptase was diminished by SBTI when trypsin and SBTI were added to cells at the same time (Figure 1).

\[\text{Figure 1} \quad \text{Effects of tc-LIGRLO, tc-OLRGIL, SLIGKV, VKGILS, trypsin, anti-IgE and calcium ionophore A23187 (CI) on tryptase release from colon mast cells. The values shown are mean±SEM for four separate experiments. Stimulus or control was incubated with cells for 15 min before termination of the reactions. }^{a}P<0.05 \text{ compared with buffer alone group (paired Student’ s } \text{t test).}\]
Induction of histamine release by agonists of PAR-2
Both PAR-2 agonists tc-LIGRLO-NH$_2$ and SLIGKV-NH$_2$ were also able to induce a dose-dependent release of histamine from colon mast cells. More than 2.5 and 2.0-fold increases in histamine release were provoked by 100 µmol/mL tc-LIGRLO-NH$_2$ and SLIGKV-NH$_2$, respectively. However, histamine release elicited by tc-LIGRLO-NH$_2$ (100 µmol/mL) was less than that induced by anti-IgE (10 µg/mL) and only half of that provoked by calcium ionophore (1 µg/mL). The reverse peptides tc-OLRGIL-NH$_2$ and VKGILS-NH$_2$ had no effect on the release of histamine when being added at concentrations up to 300 µmol/mL (Figure 2). Trypsin at the concentrations from 1.0 to 100 µg/mL was capable of provoking a dose-dependent release of histamine with a maximum of 14 ng/mL histamine being released by 100 µg/mL trypsin. Approximately 70% trypsin-induced release of histamine was reduced by SBTI when trypsin and SBTI were added at the same time to cells (Figure 2).

Time course for tc-LIGRLO-NH$_2$
The release of tryptase and histamine in response to tc-LIGRLO-NH$_2$ was maximized within 3 min following addition of 100 µmol/mL tc-LIGRLO-NH$_2$ to colon mast cells. The maximum release of tryptase and histamine was then maintained for at least 15 min (Figure 3). When tc-LIGRLO-NH$_2$, anti-IgE and calcium ionophore were incubated with cells for a prolonged period of 30 min, the amount of tryptase and histamine released appeared not being increased (Table 1).

Table 1 Effects of tc-LIGRLO, tc-OLRGIL, anti-IgE and calcium ionophore A23187 (CI) on tryptase and histamine release from colon mast cells following 30 min incubation period

| Concentration of stimulus | Tryptase (ng/mL) | Histamine (ng/mL) |
|---------------------------|-----------------|------------------|
| Buffer alone              | 8.2±0.6         | 9.5±1.7          |
| tc-LIGRLO 100 µmol/mL     | 22±3.0          | 17±1.3           |
| tc-OLRGIL 100 µmol/mL     | 8.4±2.8         | 10±1.9           |
| Anti-IgE 10 µg/mL         | 19±4.1          | 19±4.8           |
| CI 1.0 µg/mL              | 13±0.6          | 34±6.3           |

The values shown are mean±SEM for four separate experiments performed in duplicate. *P* < 0.05 compared with buffer alone group (paired Student’s t test).

Effects of pertussis toxin and metabolic inhibitors on tryptase and histamine release
Tryptase release induced by tc-LIGRLO-NH$_2$, SLIGKV-NH$_2$ and trypsin was abolished by pretreatment of colon mast cells with metabolic inhibitors or pertussis toxin (Table 2). The same treatment was also able to almost completely inhibit histamine release from mast cells (Table 3).

Table 2 Inhibition of tc-LIGRLO, SLIGKV, trypsin, anti-IgE or calcium ionophore A23187 (CI) induced tryptase release from colon mast cells by pertussis toxin (1 µg/mL) and metabolic inhibitors

| Concentration of stimulus | % inhibition of tryptase release |
|---------------------------|----------------------------------|
|                           | Pertussis toxin      | Metabolic inhibitors |
| tc-LIGRLO 100 µmol/mL     | 85±4.6                                            | 91±3.9               |
| SLIGKV 100 µmol/mL        | 91±4.8                                            | 94±3.6               |
| Trypsin 10 µg/mL          | 100±0.0                                           | 95±4.0               |
| Anti-IgE 10 µg/mL         | 87±3.0                                            | 99±0.5               |
| CI 1.0 µg/mL              | 84±8.8                                            | 89±4.7               |

The values shown are mean±SEM for four separate experiments performed in duplicate. *P* < 0.05 compared with the uninhibited control group (paired Student’s t test).
and histamine induced by them was a non-cytotoxic process, indicating that the process was not cytotoxic and required an aminopeptidase action of tc-LIGRLO-NH$_2$, a mixed type of inhibitor of tryptic enzymes.

Histamine release by SBTI, a metabolic inhibitor antimycin A which blocks the oxidative phosphorylation process of cells, and 2-deoxy-D-glucose which blocks anaerobic metabolism pathway in cells, abolished the actions of tc-LIGRLO-NH$_2$, SLIGKV, trypsin, anti-IgE as well as calcium ionophore, indicating that the release of tryptase and histamine induced by them was a non-cytotoxic process, and was dependent on cell energy supply. Tryptase and histamine release provoked by tc-LIGRLO-NH$_2$, SLIGKV, trypsin, anti-IgE and calcium ionophore were also inhibited by pretreatment of cells with pertussis toxin, suggesting that the degranulation process elicited by them was associated with the activation of G-protein coupled receptors$^{[30]}$.

Over the last decade, a number of functions of mast cell tryptase have been discovered. These include induction of microvascular leakage$^{[21]}$, accumulation and activation of eosinophils and neutrophils$^{[22,25]}$, provocation of release of IL-8 from epithelial cells$^{[30]}$. Similarly, PAR-2 agonists were found to be able to provoke the inflammatory response in the rat paw$^{[31,32]}$ and mediate eosinophil infiltration and hyperreactivity in allergic inflammation of the airway$^{[33]}$. Of particular importance is the finding that the delayed onset of inflammation was observed in protease-activated receptor-2-deficient mice$^{[34]}$. These highlighted the crucial role of tryptase and its receptor PAR-2 in inflammation. The finding that PAR-2 agonists were able to activate human colon mast cells in the current study added a new concept to the tryptase and PAR-2 theory, indicating further the importance of them in the pathogenesis of inflammation. In conclusion, the agonists of PAR-2 and trypsin are potent secretagogues of human colon mast cells, which are likely to contribute to the development of inflammatory disorders in human gut.

DISCUSSION

The finding in the current study that PAR-2 agonists were able to activate human mast cells fulfilled our hypothesis that human mast cells possess a self-amplification mechanism to IgE-dependent activation through their mediator tryptase. That is to say that upon activation, mast cells release tryptase, and the released tryptase then activates their neighbouring mast cells or acts on its host mast cells through PAR-2.

The maximum 22.5 ng/mL tryptase and 21 ng/mL histamine release induced by tc-LIGRLO-NH$_2$ were comparable to those induced by 10 µg/mL anti-IgE, indicating that the PAR-2 agonist is a potent stimulus of mast cells. SLIGKV was also able to provoke a significant tryptase and histamine release from colon mast cells, but its action appeared slightly weaker than tc-LIGRLO-NH$_2$. This could be due to the structural difference between the two molecules. As little as 1.0 µmol/mL tc-LIGRLO-NH$_2$ was able to stimulate a significant release of tryptase and histamine, suggesting further that this compound is a potent mast cell secretagogue, and the concentration of the stimulus is easy to be achieved under physiological conditions. It was little surprised to observe that trypsin was able to activate colon mast cells as there should be a relatively high concentration of trypsin in human intestinal tract, and some of them should be able to penetrate through the epithelial lining of intestine, particularly when paracellular permeability of colon was increased upon PAR-2 activation$^{[36]}$. Nevertheless, it should be interesting to learn the physiological or pathophysiological role of mast cell activation by trypsin in gastrointestinal tract in future. The fact that reversed peptides of PAR-2 agonists had little effect on tryptase and histamine release from colon mast cells proved further the specificity of the PAR-2 agonists on mast cells. The maximum release of tryptase and histamine from colon mast cells was achieved at 3 min after adding tc-LIGRLO-NH$_2$ to cells, suggesting that its action on mast cells was slower than that of neuropeptide substance P, which reached peak histamine release within 20 sec of incubation$^{[24]}$, but faster than that induced by anti-IgE and calcium ionophore, which required at least 6 min to complete$^{[21]}$.

The inhibition of trypsin induced tryptase and histamine release by SBTI, a mixed type of inhibitor of tryptic enzymes$^{[21]}$, indicating that the process was not cytotoxic and required an intact catalytic site of trypsin. Pretreatment of cells with metabolic inhibitors antymycin A which blocks the oxidative phosphorylation process of cells, and 2-deoxy-D-glucose which blocks anaerobic metabolism pathway in cells, abolished the actions of tc-LIGRLO-NH$_2$, SLIGKV, trypsin, anti-IgE as well as calcium ionophore, indicating that the release of tryptase and histamine induced by them was a non-cytotoxic process.
Furusu H, Murase K, Nishida Y, Isomoto H, Takeshima F, Mizuta Y, Hewlett BR, Riddell RH, Kohno S. Accumulation of mast cell and macrophages in focal active gastritis of patients with Crohn's disease. Hepatogastroenterology 2002; 49: 639-643

Schwab D, Hahn EG, Raithel M. Enhanced histamine metabolism: a comparative analysis of collagenous colitis and food allergy with respect to the role of diet and NSAID use. Inflamm Res 2003; 52: 142-147

Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, Raithel M. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 3071-3077

Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995; 108: 127-133

Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 174-179

He SH, Gaça MDA, Walls AF. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther 1998; 286: 289-297

He SH, Gaça MDA, Walls AF. The activation of synovial mast cells: modulation of histamine release by tryptase and chymase and their inhibitors. Eur J Pharmacol 2001; 412: 223-229

D'Andrea MR, Rogahn CJ, Andrade-Gordon P. Localization of protease-activated receptors-1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. Biotech Histochem 2000; 75: 85-90

Stenton GR, Nohara O, Dery RE, Vliagoftis H, Gilchrist M, Johri A, Wallace JL, Hollenberg MD, Mozibel R, Befus AD. Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther 2002; 302: 466-474

He SH, Xie H, He YS. Induction of tryptase and histamine release from human colon mast cells by protease inhibitors. World J Gastroenterol 2004; 10: 319-322

He SH, Xie H. Modulation of histamine release from human colon mast cells by protease inhibitors. World J Gastroenterol 2004; 10: 337-341

Buckley MG, Walters C, Wong WM, Cawley MID, Ren S, Schwartz LB, Walls AF. Mast cell activation in arthritis: detection of α- and β-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci 1997; 93: 363-370

Lowman MA, Benyon RC, Church MK. Characterisation of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol 1988; 95: 121-130

He SH, Gaça MDA, McEuen AR, Walls AF. Inhibitors of chymase as mast cell stabilising agents: the contribution of chymase in the activation of human mast cells. J Pharmacol Exp Ther 1999; 291: 517-523

Piliponsky AM, Gleich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood 2003; 101: 1998-1994

He SH, Walls AF. Human mast cell tryptase: A potent stimulus of microvascular leakage and mast cell activation. Eur J Pharmacol 1997; 337-341

He SH, Peng Q, Walls AF. Potent induction of neutrophil- and eosinophil-rich infiltration in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 1997; 159: 6216-6225

Temkin V, Kantor B, Weg V, Hartman ML, Levi-Schaffer F. Tryptase activates the mitogen-activated protein kinase activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol 2002; 169: 2662-2669

Caims JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells: Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996; 156: 275-283

Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 1999; 127: 1083-1090

Vergnolle N, Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol 1999; 163: 5064-5069

Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Burnett NW, Gater PR, Geppetti P, Bertrand C, Stevens ME. Proteinase-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002; 169: 5315-5321

Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, Foy D, Hafezi-Moghadam A, Ley K. Delayed onset of inflammation in proteinase-activated receptor-2-deficient mice. J Immunol 2000; 165: 6504-6510

Edited by Wang XL